388 related articles for article (PubMed ID: 21420491)
1. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process.
Giordani A; Kobel W; Gally HU
Eur J Pharm Sci; 2011 May; 43(1-2):1-15. PubMed ID: 21420491
[TBL] [Abstract][Full Text] [Related]
2. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective.
Raman NV; Prasad AV; Ratnakar Reddy K
J Pharm Biomed Anal; 2011 Jun; 55(4):662-7. PubMed ID: 21193280
[TBL] [Abstract][Full Text] [Related]
3. Toxicological overview of impurities in pharmaceutical products.
Jacobson-Kram D; McGovern T
Adv Drug Deliv Rev; 2007 Jan; 59(1):38-42. PubMed ID: 17188779
[TBL] [Abstract][Full Text] [Related]
4. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
Humfrey CD
Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
[TBL] [Abstract][Full Text] [Related]
5. Overview of genotoxic impurities in pharmaceutical development.
Bercu JP; Dobo KL; Gocke E; McGovern TJ
Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
[TBL] [Abstract][Full Text] [Related]
6. The assessment of impurities for genotoxic potential and subsequent control in drug substance and drug product.
Dow LK; Hansen MM; Pack BW; Page TJ; Baertschi SW
J Pharm Sci; 2013 May; 102(5):1404-18. PubMed ID: 23436613
[TBL] [Abstract][Full Text] [Related]
7. Eliminating pharmaceutical impurities: Recent advances in detection techniques.
Liu DQ; Sun M; Wu L
Curr Opin Drug Discov Devel; 2010; 13(6):748-57. PubMed ID: 21061235
[TBL] [Abstract][Full Text] [Related]
8. Drug impurities: problems and regulations.
Pifferi G; Mannucci A
Boll Chim Farm; 1999 Nov; 138(10):500-7. PubMed ID: 10765465
[TBL] [Abstract][Full Text] [Related]
9. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
Liu DQ; Chen TK; McGuire MA; Kord AS
J Pharm Biomed Anal; 2009 Sep; 50(2):144-50. PubMed ID: 19427156
[TBL] [Abstract][Full Text] [Related]
10. Quantitative assessment of cumulative carcinogenic risk for multiple genotoxic impurities in a new drug substance.
Bercu JP; Hoffman WP; Lee C; Ness DK
Regul Toxicol Pharmacol; 2008 Aug; 51(3):270-7. PubMed ID: 18550240
[TBL] [Abstract][Full Text] [Related]
11. Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review.
Reddy AV; Jaafar J; Umar K; Majid ZA; Aris AB; Talib J; Madhavi G
J Sep Sci; 2015 Mar; 38(5):764-79. PubMed ID: 25556762
[TBL] [Abstract][Full Text] [Related]
12. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs).
Elder DP; Lipczynski AM; Teasdale A
J Pharm Biomed Anal; 2008 Nov; 48(3):497-507. PubMed ID: 18657926
[TBL] [Abstract][Full Text] [Related]
13. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
[TBL] [Abstract][Full Text] [Related]
14. Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment.
Snodin DJ; McCrossen SD
Regul Toxicol Pharmacol; 2012 Jul; 63(2):298-312. PubMed ID: 22507740
[TBL] [Abstract][Full Text] [Related]
15. Impurities in drug substances and drug products: new approaches to quantification and qualification.
Berridge JC
J Pharm Biomed Anal; 1995 Dec; 14(1-2):7-12. PubMed ID: 8833961
[TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical impurities: regulatory perspective for Abbreviated New Drug Applications.
Basak AK; Raw AS; Al Hakim AH; Furness S; Samaan NI; Gill DS; Patel HB; Powers RF; Yu L
Adv Drug Deliv Rev; 2007 Jan; 59(1):64-72. PubMed ID: 17196703
[TBL] [Abstract][Full Text] [Related]
17. A perspective on testing of existing pharmaceutical excipients for genotoxic impurities.
Brusick DJ
Regul Toxicol Pharmacol; 2009 Nov; 55(2):200-4. PubMed ID: 19607870
[TBL] [Abstract][Full Text] [Related]
18. Strategies for the investigation and control of process-related impurities in drug substances.
Argentine MD; Owens PK; Olsen BA
Adv Drug Deliv Rev; 2007 Jan; 59(1):12-28. PubMed ID: 17189658
[TBL] [Abstract][Full Text] [Related]
19. International Conference on Harmonisation; guidance on Q9 Quality Risk Management; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2006 Jun; 71(106):32105-6. PubMed ID: 16795933
[TBL] [Abstract][Full Text] [Related]
20. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
